"Zepbound: A Promising Treatment for Sleep Apnea and Weight Loss, Says Eli Lilly"

Eli Lilly's weight loss drug Zepbound has been found to reduce obstructive sleep apnea in adults with obesity, according to the drugmaker. The drug was shown to significantly decrease the number of breathing interruptions during sleep in two studies of adults with obesity and moderate to severe obstructive sleep apnea. These findings could potentially impact insurance coverage for the weight loss drug and may lead to its submission to the FDA later this year.